Gainers

• Scinai Immunotherapeutics (NASDAQ:SCNI) shares moved upwards by 145.6% to $1.12 during Friday's pre-market session. The company's market cap stands at $1.6 million.
• Organon (NYSE:OGN) stock increased by 28.37% to $11.04. The market value of their outstanding shares is at $2.2 billion.
• iTonic Holdings (NASDAQ:ITOC) stock increased by 21.96% to $0.37. The market value of their outstanding shares is at $5.1 million.
• Tivic Health Systems (NASDAQ:TIVC) shares rose 18.74% to $1.33. The market value of their outstanding shares is at $3.2 million.
• Addex Therapeutics (NASDAQ:ADXN) stock rose 14.0% to $7.0. The company's market cap stands at $7.5 million.
• Lunai Bioworks (NASDAQ:LNAI) stock increased by 13.88% to $0.35. The company's market cap stands at $11.0 million.

Losers

• Sonoma Pharmaceuticals (NASDAQ:SNOA) shares fell 26.1% to $1.33 during Friday's pre-market session. The market value of their outstanding shares is at $3.1 million.
• Citius Pharmaceuticals (NASDAQ:CTXR) stock declined by 24.79% to $0.7. The market value of their outstanding shares is at $20.8 million.
• Tevogen Bio Holdings (NASDAQ:TVGN) stock decreased by 20.83% to $5.55. The company's market cap stands at $28.3 million.
• EUDA Health Holdings (NASDAQ:EUDA) stock fell 14.93% to $9.75. The company's market cap stands at $28.8 million.
• NextCure (NASDAQ:NXTC) shares decreased by 11.7% to $10.95. The company's market cap stands at $43.4 million.
• XORTX Therapeutics (NASDAQ:XRTX) shares decreased by 7.67% to $2.56. The company's market cap stands at $4.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.